The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | The future of Tumor Treating Fields (TTFields) in managing lung cancer
Minesh Mehta, MD, Miami Cancer Institute, Miami, FL, explores the emerging role of Tumor Treating Fields (TTFields) in the management non-small cell lung cancer (NSCLC). The Phase III LUNAR (NCT02973789) and METIS (NCT02831959) trials demonstrated the efficacy of TTFields and additional trials should be conducted to further assess the novel treatment modality in patients with both brain metastases and extracranial disease. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Chimerix
Consulting or Advisory Role – Kazia Therapeutics; Mevion Medical Systems; Novocure; Telix Pharmaceuticals; Xoft; ZappRx
Patents, Royalties, Other Intellectual Property – WARF patent 14/934,27, TOPICAL VASOCONSTRITOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY
